|
[1]
|
Gas6 in chronic liver disease—a novel blood-based biomarker for liver fibrosis
Cell Death Discovery,
2023
DOI:10.1038/s41420-023-01551-6
|
|
|
|
|
[2]
|
Two-Front War on Cancer—Targeting TAM Receptors in Solid Tumour Therapy
Cancers,
2022
DOI:10.3390/cancers14102488
|
|
|
|
|
[3]
|
Construction of 2DE Patterns of Plasma Proteins: Aspect of Potential Tumor Markers
International Journal of Molecular Sciences,
2022
DOI:10.3390/ijms231911113
|
|
|
|
|
[4]
|
A review on the role of GAS6 and GAS6-AS1 in the carcinogenesis
Pathology - Research and Practice,
2021
DOI:10.1016/j.prp.2021.153596
|
|
|
|
|
[5]
|
Intrinsic and Extrinsic Control of Hepatocellular Carcinoma by TAM Receptors
Cancers,
2021
DOI:10.3390/cancers13215448
|
|
|
|
|
[6]
|
A review on the role of GAS6 and GAS6-AS1 in the carcinogenesis
Pathology - Research and Practice,
2021
DOI:10.1016/j.prp.2021.153596
|
|
|
|
|
[7]
|
Identification of Kinome Representatives with Neuroprotective Activity
Neurochemical Journal,
2020
DOI:10.1134/S1819712420040133
|
|
|
|
|
[8]
|
TAM kinase inhibition and immune checkpoint blockade– a winning combination in cancer treatment?
Expert Opinion on Therapeutic Targets,
2020
DOI:10.1080/14728222.2021.1869212
|
|
|
|
|
[9]
|
The Emerging Role of TYRO3 as a Therapeutic Target in Cancer
Cancers,
2018
DOI:10.3390/cancers10120474
|
|
|
|
|
[10]
|
Dynamics of Axl Receptor Shedding in Hepatocellular Carcinoma and Its Implication for Theranostics
International Journal of Molecular Sciences,
2018
DOI:10.3390/ijms19124111
|
|
|
|
|
[11]
|
The non-invasive serum biomarker soluble Axl accurately detects advanced liver fibrosis and cirrhosis
Cell Death & Disease,
2017
DOI:10.1038/cddis.2017.554
|
|
|
|
|
[12]
|
The non-invasive serum biomarker soluble Axl accurately detects advanced liver fibrosis and cirrhosis
Cell Death and Disease,
2017
DOI:10.1038/cddis.2017.554
|
|
|
|